Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Study sheds light on the role of fibro-adipogenic progenitors in muscle regeneration and degeneration

A recent study has shed new light on the role of fibro-adipogenic progenitors (FAPs) in muscle regeneration, fibrosis, and degeneration.

5 Mar 2025

Macrophage-targeted therapy could enhance cardiac regeneration and myocardial repair

A new review published in Genes & Diseases highlights macrophage-targeted therapy as a promising frontier in cardiac regeneration and myocardial repair.

5 Mar 2025

New insights into miRNA roles in diabetic cardiomyopathy immune regulation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM), an independent diabetes complication, is characterized by abnormalities in myocardial structure, function, and metabolism, including diminished myocardial contractility, myocardial hypertrophy, and fibrosis.

5 Mar 2025

Review sheds light on the mechanistic role of long non-coding RNAs in liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a global health challenge, affecting nearly 30% of adults worldwide.

28 Feb 2025

Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025

The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman's Health Imperative-and the National Association of Community Health Workers (NACHW) announce their collaboration to address idiopathic pulmonary fibrosis (IPF) as a chronic disease on Rare Disease Day 2025.

28 Feb 2025

Understanding the impact of SLC transporters on liver disease progression

Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting approximately 30% of the population.

28 Feb 2025

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).

25 Feb 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

22 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025

Antioxidant-enzyme interactions and their role in non-communicable diseases

Oxidative stress, caused by an imbalance between reactive oxygen species (ROS) and antioxidant defenses, plays a central role in the development of non-communicable diseases (NCDs).

21 Feb 2025

Targeting FGFR mutations offers new hope for bone repair in skeletal disorders

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect craniofacial and mandibular development.

21 Feb 2025

New 3D lung model advances respiratory medicine research

Respiratory diseases are a challenging problem to treat. Inhalable medicines are a promising solution that depend on the ability to deliver tiny particles known as aerosols to the correct location in the lungs at the correct dosage.

20 Feb 2025

Inhalable gene therapy tested for cystic fibrosis treatment in the UK and Europe

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

20 Feb 2025

New discovery offers hope in the battle against pulmonary fibrosis

A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe.

20 Feb 2025

Vitamin E significantly improves liver health in MASH patients, new study finds

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in patients with MASH, with no major safety concerns reported.

19 Feb 2025

Innovative method improves understanding of cellular and molecular mechanisms in kidney diseases

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic kidney disease (CKD), at both the cellular and molecular levels.

19 Feb 2025

Tampere University licenses drug for Epidermolysis Bullosa to Theravia

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the Paris region of France.

19 Feb 2025

FDA-approved osteoporosis drug may treat rare genetic heart disease

A research team co-led by scientists at the University of Arizona College of Medicine – Tucson found that an osteoporosis drug might counter a rare genetic mutation underlying a type of heart disease.

18 Feb 2025

Researchers develop a way to treat muscular atrophy using regenerative medicine

Researchers from Tokyo Metropolitan University have developed a way to treat ageing-related muscular atrophy using regenerative medicine.

17 Feb 2025

Infants with cystic fibrosis show stunted gut microbiome development

Findings from a new Dartmouth-led study, published in the journal mBio, highlight key differences in the gut microbiome (communities of bacteria) of infants with cystic fibrosis (CF) compared to that of healthy infants, and how these alterations may adversely affect their health.

14 Feb 2025